These cancers include aggressive subtypes, such as high-grade endometrioid carcinomas, serous carcinomas, and clear cell carcinomas, where ARID1A mutations contribute significantly to tumor progression, genomic instability, and treatment resistance [75]. This evidence concerns the gene ARID1A and neoplasm.